New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
16:13 EDTQGENQIAGEN announces three separate agreements to add biomarkers
QIAGEN announced three separate agreements that add multiple biomarkers to QIAGEN's development pipeline of diagnostics for Personalized Healthcare applications. QIAGEN intends to develop new diagnostics to guide treatment decisions, including companion diagnostics paired with medicines, based on these biomarkers. Most of these assays will be designed to run on the QIAsymphony RGQ modular laboratory workflow automation system as well as QIAGEN's next-generation sequencing workflows currently in development. QIAGEN has made a strategic equity investment in Drug Response Dx GmbH with the option to obtain worldwide rights to biomarkers for evaluation of rheumatoid arthritis patients to guide treatment with TNF-alpha inhibitors, which are widely prescribed for treatment of RA. QIAGEN has agreed to license exclusive worldwide rights from Insight Genetics for the RET, ROS1 and DEPDC1 biomarkers for use in non-small cell lung cancer, the most common form of lung cancer. QIAGEN Marseille has licensed exclusive worldwide rights to a biomarker for mutations of the HSP110 gene, which allows for identification of specific types of colorectal cancer, from InsermTransfert, the technology transfer arm of the French National Institute of Health and Medical Research.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
16:13 EDTQGENQIAGEN, 10x Genomics enter co-marketing, co-development collaboration
QIAGEN announced a collaboration with 10x Genomics to develop and promote comprehensive solutions for next-generation sequencing, or NGS, single-cell biology and bioinformatics. This collaboration includes: Optimizing QIAGEN's sample technologies for use with 10x Genomics GemCode and Chromium systems. This includes QIAGEN's MagAttract HMW DNA kit to deliver high-quality, high molecular weight, or HMW, DNA through a simple and fast workflow. The enhanced performance of integrating QIAGEN and 10x Genomics technologies will be shown at the Advances in Genome Biology and Technology, or AGBT, meeting in Orlando, FL, from February 10-13. Supporting complete workflows in single-cell biology by leveraging 10x Genomics' revolutionary GemCode technology with QIAGEN's leading single-cell biology portfolio and QIAseq NGS solutions. Investigating the implementation of 10x Genomics' GemCode technology with QIAGEN's proprietary GeneReader NGS System, the world's first complete NGS workflow designed for any lab. The combination will result in upgraded capabilities of QIAGEN's Sample to Insight solutions for NGS such as allowing customers to detect structural variants, haplotypes and other valuable long-range information from DNA inputs as little as 1ng. Enabling the processing and analysis of 10x Genomics' "Linked-Reads" with QIAGEN's suite of leading bioinformatics solutions. These efforts aim to address the challenges of data analysis, interpretation, clinical decision-support, and reporting that rely on testing for long-range phasing and structural variants in genomics. Co-marketing each other's applications, including QIAGEN's sample technologies, QIAseq NGS solutions, and QIAGEN Bioinformatics along with 10x GemCode Platform and Chromium products.
February 2, 2016
16:14 EDTQGENQIAGEN announces agreement with CosmosID Inc.
QIAGEN announced new partnerships to "enhance the profile and expand the use of its market leading bioinformatics solutions for microbiome, metagenomics and other applications." The company said, "QIAGEN Bioinformatics signed an agreement with genomics big data company CosmosID Inc., to allow users of QIAGEN's CLC Genomics Workbench to access and integrate CosmosID's metagenomics analysis platform into their QIAGEN bioinformatics platform. CosmosID's platform allows users to identify and characterize microbial communities from whole genome shotgun data and to determine their relative abundance. The new plug-in expands the range of metagenomic and microbiome applications supported by QIAGEN's microbial genomics solution enabling researchers in fields such as infectious disease, animal health, agriculture, environmental and food safety to use shotgun metagenomics analysis for routine testing employing next-generation sequencing."
16:12 EDTQGENQIAGEN says 'on course' to achieve the 2016 goals
Subscribe for More Information
16:12 EDTQGENQIAGEN reports Q4 adjusted EPS 31c, consensus 32c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use